CliffBio
small molecule

NEXAVAR

SORAFENIB TOSYLATE

Loss of exclusivitySeptember 2028latest FDA-listed patent expiry
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEXAVAR
Active ingredientSORAFENIB TOSYLATE
StrengthEQ 200MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2005
Marketing statusRX

Listed patents

PatentExpiresType
9737488September 2028product
8877933December 2027substance, product

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NEXAVAR patent cliff — loss of exclusivity September 2028 | CliffBio